Matches in SemOpenAlex for { <https://semopenalex.org/work/W2997188552> ?p ?o ?g. }
- W2997188552 endingPage "385" @default.
- W2997188552 startingPage "371" @default.
- W2997188552 abstract "In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key phase 3 trials of tyrosine kinase inhibitors (TKI) comparing with each other, treatment free remission (TFR) and selection of TKI. Upcoming concepts and related trials in the management of chronic myeloid leukemia (CML) along with future directions have been touched upon. PubMed, Embase, Google, Cochrane library and Medline were searched to identify relevant literature for the review. Clinicaltrial.gov was searched for upcoming data and trials. There are lot of gap in pharmacokinetics and pharmacodynamics of TKI. Imatinib appears to be the safest TKI. Newer TKI’s achieve better achievement of therapeutic milestones, deeper molecular response and less chances of progression of CML compared to imatinib. Newer TKI appears to be better choice for achieving TFR. When the objective is survival, imatinib is still the TKI of choice. Primary prophylaxis with antiplatelet drugs for TKI having cardiovascular and thromboembolic side effects should be considered. Pharmacogenetic data of TKI is still immature to guide in therapeutic decision making in clinical practice. There is need for further research in pharmacology and pharmacogenomics of newer TKI’s. Randomized controlled trials are required to decide the optimum TKI for TFR. Safe and effective TKI for targeting T315I mutation, CML accelerated phase and blast crisis are an active area of research." @default.
- W2997188552 created "2020-01-10" @default.
- W2997188552 creator A5000530935 @default.
- W2997188552 creator A5017135484 @default.
- W2997188552 date "2020-01-03" @default.
- W2997188552 modified "2023-10-16" @default.
- W2997188552 title "Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective" @default.
- W2997188552 cites W1827459324 @default.
- W2997188552 cites W1937674431 @default.
- W2997188552 cites W1966530290 @default.
- W2997188552 cites W1967920366 @default.
- W2997188552 cites W1978349958 @default.
- W2997188552 cites W1978821257 @default.
- W2997188552 cites W1990392466 @default.
- W2997188552 cites W1994327535 @default.
- W2997188552 cites W1997730029 @default.
- W2997188552 cites W2000380354 @default.
- W2997188552 cites W2002298886 @default.
- W2997188552 cites W2003278476 @default.
- W2997188552 cites W2008090631 @default.
- W2997188552 cites W2008225112 @default.
- W2997188552 cites W2013850642 @default.
- W2997188552 cites W2019633460 @default.
- W2997188552 cites W2020103507 @default.
- W2997188552 cites W2023187096 @default.
- W2997188552 cites W2026103827 @default.
- W2997188552 cites W2034074778 @default.
- W2997188552 cites W2035910722 @default.
- W2997188552 cites W2037398716 @default.
- W2997188552 cites W2037602803 @default.
- W2997188552 cites W2052923507 @default.
- W2997188552 cites W2055515709 @default.
- W2997188552 cites W2057114258 @default.
- W2997188552 cites W2057206328 @default.
- W2997188552 cites W2057257241 @default.
- W2997188552 cites W2059502243 @default.
- W2997188552 cites W2060384943 @default.
- W2997188552 cites W2064367288 @default.
- W2997188552 cites W2065902287 @default.
- W2997188552 cites W2072834954 @default.
- W2997188552 cites W2073587057 @default.
- W2997188552 cites W2074740555 @default.
- W2997188552 cites W2076678352 @default.
- W2997188552 cites W2084186145 @default.
- W2997188552 cites W2093197708 @default.
- W2997188552 cites W2093802822 @default.
- W2997188552 cites W2097946794 @default.
- W2997188552 cites W2103796073 @default.
- W2997188552 cites W2104694028 @default.
- W2997188552 cites W2111072132 @default.
- W2997188552 cites W2124524221 @default.
- W2997188552 cites W2132656575 @default.
- W2997188552 cites W2137271938 @default.
- W2997188552 cites W2147109509 @default.
- W2997188552 cites W2148857879 @default.
- W2997188552 cites W2150604072 @default.
- W2997188552 cites W2153484612 @default.
- W2997188552 cites W2155229204 @default.
- W2997188552 cites W2156145496 @default.
- W2997188552 cites W2158977917 @default.
- W2997188552 cites W2162340188 @default.
- W2997188552 cites W2171273906 @default.
- W2997188552 cites W2189113171 @default.
- W2997188552 cites W2198493462 @default.
- W2997188552 cites W2260921597 @default.
- W2997188552 cites W2314938037 @default.
- W2997188552 cites W2329648702 @default.
- W2997188552 cites W2338672629 @default.
- W2997188552 cites W2339658711 @default.
- W2997188552 cites W2339943063 @default.
- W2997188552 cites W2343511371 @default.
- W2997188552 cites W2344214880 @default.
- W2997188552 cites W2397234997 @default.
- W2997188552 cites W2408914441 @default.
- W2997188552 cites W2415074623 @default.
- W2997188552 cites W2473480037 @default.
- W2997188552 cites W2474424869 @default.
- W2997188552 cites W2495072828 @default.
- W2997188552 cites W2511069927 @default.
- W2997188552 cites W2518117171 @default.
- W2997188552 cites W2528188718 @default.
- W2997188552 cites W2532456746 @default.
- W2997188552 cites W2548191897 @default.
- W2997188552 cites W2549662312 @default.
- W2997188552 cites W2550643238 @default.
- W2997188552 cites W2560342075 @default.
- W2997188552 cites W2565128576 @default.
- W2997188552 cites W2586577682 @default.
- W2997188552 cites W2590307110 @default.
- W2997188552 cites W2611896377 @default.
- W2997188552 cites W2738693400 @default.
- W2997188552 cites W2759146932 @default.
- W2997188552 cites W2766187515 @default.
- W2997188552 cites W2785001175 @default.
- W2997188552 cites W2785477024 @default.
- W2997188552 cites W2786497541 @default.
- W2997188552 cites W2790692615 @default.
- W2997188552 cites W2791310037 @default.